Decade in Medicine | MD Magazine
The MD Magazine Decade in Medicine condition center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.
Related Articles
Cluster Headache Often Comorbid with Fibromyalgia, Migraine
A study found frequent comorbidity between cluster headache, fibromyalgia, and migraine, as well as heightened depression and sleep disturbance among these individuals.
Positive Results Observed with Baricitinib, Phototherapy for Severe Vitiligo
These findings highlight the efficacy and tolerance of treatment with oral baricitinib along with phototherapy among those with the most severe form of vitiligo.
FDA Grants Tentative Approval to Generic Version of Rifaximin for IBS-D
The approval of Amneal Pharmaceuticals’ generic version of rifaximin 550 mg oral tablets is tentative due to the product’s involvement in litigation.
HDL Antioxidant Function Diminished in Patients with HFpEF, Study Finds
Increases in oxidized HDL levels were linked to HFpEF in new analyses, suggesting reduced antioxidant HDL function is present in this patient population.
Shreena K. Gandhi, MBBS: Recognizing Fibromyalgia as a Continuous Variable, Trait Diagnosis
Gandhi discussed examining social security disability rates and how SSD criteria may clash with a trait disease like fibromyalgia.
Patient Factors Influence Semaglutide Initiation After Obesity Diagnosis
Approximately 2.0% of commercially insured individuals with obesity, but not diabetes, initiated semaglutide within 6 months of diagnosis.
Phosphatidylethanol Outperforms Traditional Alcohol Biomarkers for Detecting MetALD
Phosphatidylethanol outperformed several indirect blood-based alcohol biomarkers for differentiating MetALD from MASLD.
New Data Suggest Potential of VP-315 as Treatment for Basal Cell Carcinoma
These topline findings highlight the potential of VP-315, an investigational oncolytic peptide, as a first line therapy for basal cell carcinoma.
Dupilumab Demonstrates Efficacy for Severe Uncontrolled CRSwNP Up Until 1 Year
Dupilumab improves severe CRSwNP symptoms, such as nasal obstruction and quality of life, showing significant efficacy within 6-12 months.
Kidney Compass: Atacicept for IgAN with Jonathan Barratt, PhD, at Kidney Week 2024
Neuen, Wadhwani, and Barratt discuss atacicept promise in IgA nephropathy based on phase 2b ORIGIN OLE results, at-home use, and the future of kidney disease…